Detalhe da pesquisa
1.
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
N Engl J Med
; 376(16): 1517-1526, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28304227
2.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
N Engl J Med
; 376(16): 1527-1539, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28304242
3.
CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
Arterioscler Thromb Vasc Biol
; 34(9): 2106-14, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24969776
4.
Relationship between atorvastatin dose and the harm caused by torcetrapib.
J Lipid Res
; 53(11): 2436-42, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22941786
5.
Effect of torcetrapib on the progression of coronary atherosclerosis.
N Engl J Med
; 356(13): 1304-16, 2007 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-17387129
6.
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
N Engl J Med
; 356(16): 1620-30, 2007 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-17387131
7.
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med
; 357(21): 2109-22, 2007 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17984165
8.
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
Arterioscler Thromb Vasc Biol
; 28(1): 148-54, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17951324
9.
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
BioDrugs
; 33(5): 571-579, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31529318
10.
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Lancet
; 370(9582): 153-160, 2007 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-17630038
11.
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
Arterioscler Thromb Vasc Biol
; 27(5): 1132-8, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17322101
12.
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
J Clin Lipidol
; 12(4): 958-965, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29685591
13.
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
J Am Heart Assoc
; 4(8): e002171, 2015 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-26307570
14.
Torcetrapib and atorvastatin.
N Engl J Med
; 353(14): 1527-9; author reply 1527-9, 2005 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-16207861
15.
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Ann Med
; 42(6): 447-64, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20645885
16.
Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials.
J Atheroscler Thromb
; 17(5): 526-35, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228610
17.
Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future.
Pharmacol Rev
; 59(1): 40-53, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17329547
18.
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Curr Med Res Opin
; 23(4): 885-94, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17407645
19.
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
J Am Coll Cardiol
; 48(9): 1774-81, 2006 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17084249
20.
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
J Am Coll Cardiol
; 48(9): 1782-90, 2006 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17084250